Last reviewed · How we verify
Antibiotics only
Antibiotics kill or inhibit bacterial pathogens through various mechanisms including cell wall disruption, protein synthesis inhibition, or DNA damage.
Antibiotics kill or inhibit bacterial pathogens through various mechanisms including cell wall disruption, protein synthesis inhibition, or DNA damage. Used for Bacterial infections (various types depending on specific antibiotic).
At a glance
| Generic name | Antibiotics only |
|---|---|
| Sponsor | George Washington University |
| Drug class | Antibiotic (broad class) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Antibiotics are a broad class of antimicrobial agents that target bacterial cells through multiple distinct mechanisms depending on the specific antibiotic type. Common mechanisms include inhibition of bacterial cell wall synthesis (beta-lactams, glycopeptides), disruption of protein synthesis (aminoglycosides, tetracyclines, macrolides), inhibition of nucleic acid synthesis (fluoroquinolones), or metabolic pathway disruption (sulfonamides). These mechanisms selectively target bacterial cells while minimizing harm to human host cells.
Approved indications
- Bacterial infections (various types depending on specific antibiotic)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, vomiting)
- Allergic reactions (rash, urticaria)
- Photosensitivity (tetracyclines)
- Tendinopathy (fluoroquinolones)
- Clostridium difficile infection
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Single-arm, Prospective Study of the Efficacy and Safety of Paiteling®Antibacterial Liquid in the Treatment of Persistent Cervical HR-HPV Infection (PHASE4)
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery (PHASE4)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antibiotics only CI brief — competitive landscape report
- Antibiotics only updates RSS · CI watch RSS
- George Washington University portfolio CI